ORIGINAL PAPER
The relationship between the Chinese visceral adiposity index and the presence of nonalcoholic fatty liver disease in obese children – a pilot study
 
More details
Hide details
1
Department of Paediatrics, Medical and Clinical Studies Research Institute, National Research Centre, Egypt
 
2
Department of Clinical and Chemical Pathology, Medical and Clinical Studies Research Institute, National Research Centre, Egypt
 
 
Submission date: 2022-01-20
 
 
Final revision date: 2022-05-07
 
 
Acceptance date: 2022-05-07
 
 
Publication date: 2022-09-30
 
 
Pediatr Pol 2022;97(3):229-235
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Nonalcoholic fatty liver disease (NAFLD) has become a major contributor to chronic paediatric liver disease. The Chinese visceral adiposity index (CVAI) is an emerging indicator of visceral adiposity. How­ever, there has been no research on the association between CVAI and the presence of NAFLD in obese children. The aim of the study was to investigate the association of CVAI with the occurrence of NAFLD in obese children with body mass index (BMI) > 30 and to compare the diagnostic execution of CVAI with other traditional markers of visceral adiposity.

Material and methods:
We enrolled 153 obese children (63 male, 90 female) with an age range of 9 to 18 years. NAFLD was diagnosed via ultrasonographic evidence of fatty liver.

Results:
Visceral adiposity indices were calculated. The complete lipid profile, liver enzyme alanine aminotransferase (ALT), fasting blood glucose (FBG), fasting insulin, HbA1c, and insulin resistance non-NAFLD were calculated using the homeostasis model (HOMA-IR). The obese subjects were divided into 2 groups: the NAFLD group (53 [34.7%] obese children) and the non-NAFLD group (100 obese children). In the NAFLD group, 33 were boys and 20 were girls, with a mean age of 13.0 ± 2.99 years. The frequency of metabolic syndrome was 26.71% of participants. CVAI was significantly higher (p = 0.001) in obese children with NAFLD. CVAI had a statistically significant positive correlation with HOMA-IR, FBS, fasting insulin, and LDL (r = 0.227, p = 0.005), (r = 0.183, p = 0.024), (r = 0.267, p = 0.006), (r = 0.224, p = 0.006), respectively, and negatively correlated to HDL (r = –0.267, p = 0.001).

Conclusions:
The results suggest that CVAI was strongly associated with IR. The results of linear multiple regressions to predict NAFLD showed that CVAI, VAI, and visceral fat thickness were the most independent predictors. The receiver operating characteristic curve (ROC) showed that CVAI was the best predictor of NAFLD among obese children.
REFERENCES (25)
1.
Suri A, Song E, van Nispen J, et al. Advances in the epidemiology, diagnosis, and management of pediatric fatty liver disease reviews. Clin Ther 2021; 43: 438-454.
 
2.
Yu EL, Golshan S, Harlow KE, et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J Pediatr 2019; 207: 64-70.
 
3.
Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol 2018; 31: 288-295.
 
4.
Pawar SV, Zanwar VG, Choksey AS, et al. Most overweight and obese Indian children have nonalcoholic fatty liver disease. Ann Hepatol 2016; 15: 853-861.
 
5.
Ezzat WM, Ragab S, Ismail NA, et al. Frequency of non-alcoholic fatty liver disease in overweight/obese children and adults: clinical, sonographic picture and biochemical assessment. Journal of Genetic Engineering and Biotechnology 2012; 10: 221-227.
 
6.
Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64: 319-334.
 
7.
Zimmet P, Alberti GKMM, Kaufman F, et al. The metabolic syndrome in children and adolescents. An IDF consensus report. Pediatr Diabetes 2007; 8: 299-306.
 
8.
Xia MF, Chen Y, Lin HD, et al. A indicator of visceral adipose dysfunction to evaluate metabolic health in adult Chinese. Sci Rep 2016; 6: 38214.
 
9.
Xia MF, Lin HD, Chen LY, et al. Association of visceral adiposity and its longitudinal increase with the risk of diabetes in Chinese adults: a prospective cohort study. Diabetes Metab Res Rev 2018; 34: e3048.
 
10.
Li B, Lai X, Yan C, Jia X, Li Y. The associations between neutrophil-to-lymphocyte ratio and the Chinese Visceral Adiposity Index, and carotid atherosclerosis and atherosclerotic cardiovascular disease risk. Exp Gerontol 2020; 139: 111019.
 
11.
Luxiang S, Rui L, Yang Z, et al. Association between Chinese visceral adiposity index and incident type 2 diabetes mellitus in Japanese adults. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; 14: 3743-3751.
 
12.
Egyptian growth curves. Diabetes Endocrine Metabolism Pediatric Unit Cairo University Children’s Hospital, 2009. Available at: http://dempuegypt.blogspot.com (Accessed: 10.03.2021).
 
13.
Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
 
14.
Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97: 2482-2488.
 
15.
Anderson EL, Howe LD, Jones HE, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015; 10: e0140908.
 
16.
Rashdan M, Muhammad J, Azriyanti A. Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity. J Pediatr Endocrinol Metab 2020; 33: 247-253.
 
17.
Villanueva-Ortega E, Garcés-Hernández MJ, Herrera-Rosas A, et al. Gender-specific differences in clinical and metabolic variables associated with NAFLD in a Mexican pediatric population. Ann Hepatol 2019; 18: 693-700.
 
18.
Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci 2016; 17: 947.
 
19.
Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015; 10: e0140908.
 
20.
Ballestri S, Nascimbeni F, Baldelli E, MarrazzoA, Romagnoli D, LonardoA. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017; 34: 1291-1326.
 
21.
Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spec­trum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
 
22.
Molleston JP, Schwimmer JB, Yates KP, et al. Histological abnormal­ities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164: 707-713.
 
23.
Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, di­agnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019; 5: 11-21.
 
24.
Abeer MNE, Abd ElBaky, Ismail NA, Abo-Hashesh MM, ElShaer TF, Abd El Aziz SH, Rasheed IA. Non-alcoholic fatty liver disease (NAFLD) spectrum in children with type 1 diabetes mellitus evaluated with non-invasive fibrosis score and instrument: a cross-sectional study. Pediatr Pol 2021; 96: 223-230.
 
25.
de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48 Suppl 1: S104-S112.
 
Journals System - logo
Scroll to top